Overview

Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
To assess the feasibility of using rhBMP-2/CPM in OWO as a surgical model for pharmacodynamic studies, with assessment of the following parameters: - Injecting the desired volume of rhBMP-2/CPM within the defect - Conducting longitudinal radiographic absorptiometry of the tibial defect in the presence of rhBMP-2/CPM.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer